Clinical trials
Non-Small Cell Lung Cancer With EGFR Mutation clinical trials
Below are recruiting non-small cell lung cancer with egfr mutation clinical trials, each written for real people, not researchers. We’re tracking 403 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75 - NCT07239661Recruiting
Acupuncture plus immunotherapy for advanced lung cancer
This trial tests whether adding electroacupuncture to a PD-1 inhibitor (a type of immunotherapy) can help people with advanced non-small cell lung cancer who have limited activity levels. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07264647RecruitingPhase 2
Chemo-immunotherapy before surgery for stage III lung cancer
This trial tests combining chemotherapy with immunotherapy before surgery for people with stage III non-small cell lung cancer that has a PD-L1 level of 1% or higher. The goal is to see if this approach can improve outcomes.
Rome, Roma (RM)Ages 18–99 - NCT07279935RecruitingPhase 4
Testing osimertinib with chemo for lung cancer that returned
This trial is for people with a specific type of lung cancer (EGFR-mutated non-small cell) that has come back in another part of the body after finishing treatment with osimertinib after surgery. It tests whether giving osimertinib again plus chemotherapy can help control the cancer.
BeijingAges 18 years+ - NCT07288034RecruitingPhase 2
Immunotherapy biomarkers for advanced lung cancer
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
Goodyear, ArizonaAges 18 years+ - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT07309952RecruitingPhase 2
Chemo, immunotherapy and targeted radiation before surgery for advanced lung cancer
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07323056RecruitingPhase 2
Neoadjuvant drug combo for stage 3 EGFR-mutant lung cancer
This trial tests two drugs, sacituzumab tirumotecan and limertinib, given before surgery to people with stage 3 non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can shrink the tumor enough to allow surgery.
ShanghaiAges 18 years+ - NCT07323641RecruitingPhase 2
Telisotuzumab Vedotin and Osimertinib for Advanced Lung Cancer
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75 - NCT07330596RecruitingPhase 2
Study of QL1706 plus chemo for lung cancer that got worse after immunotherapy
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
HefeiAges 18–75 - NCT07336732RecruitingPhase 2
New targeted drug with chemo for rare EGFR lung cancer
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
GuangzhouAges 18 years+ - NCT07348965Recruiting
High-dose furmonertinib for EGFR-mutant lung cancer that spread to the brain lining
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
Guangzhou, GuangdongAges 18–75 - NCT07361237RecruitingPhase 1
HJ-004-02 tablet for EGFR-mutated lung cancer
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07361705RecruitingPhase 1
Zorifertinib and osimertinib for lung cancer that spread to the brain lining
This trial tests a new drug, zorifertinib, combined with osimertinib for people whose lung cancer has spread to the lining of the brain (meninges) and continued to grow despite osimertinib treatment. The goal is to see if this combination can better control the brain spread.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07362459RecruitingPhase 3
Study of SCTB14 for untreated advanced non-small cell lung cancer
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07362940RecruitingPhase 1/Phase 2
Study of GEN-725 plus Dositinib for advanced EGFR-positive lung cancer
This trial tests a new combination of two drugs (GEN-725 and Dositinib) for people with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. It aims to see if this combination can help when standard treatments stop working or as a first treatment.
BeijingAges 18–75 - NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT07379476RecruitingPhase 2
Targeted treatment for remaining spots in EGFR lung cancer
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
Hong KongAges 18 years+ - NCT07392658RecruitingPhase 2
Amivantamab plus chemo for EGFR-mutated lung cancer
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
Roma, Roma (RM)Ages 18–99 - NCT01994057Recruiting
Looking back at EGFR-targeted pills for lung cancer
This study looks back at how people with non-small cell lung cancer (NSCLC) were treated with EGFR-targeted medicines (gefitinib, erlotinib, and osimertinib). It may help doctors understand which patients benefit most and what side effects to expect.
Guangzhou, GuangdongAges 18–85 - NCT02511288Recruiting
Blood tests to monitor advanced lung cancer during care
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
AnnecyAges 18 years+ - NCT03042221Recruiting
Early re-biopsy to find why tumors survive targeted drugs
This study takes a small tumor sample early after starting targeted treatment (or uses blood if a biopsy isn’t possible) to look for clues—called biomarkers—about why some tumor cells survive. The results may help improve how future patients’ treatments are chosen for certain lung cancer gene mutations.
Aurora, ColoradoAges 18–85 - NCT07398599Recruiting
Double-dose targeted therapy plus chemo for lung cancer spread to brain lining
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
Nanchang, JiangxiAges 18–99
Hear when a new Non-Small Cell Lung Cancer With EGFR Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-small cell lung cancer with egfr mutation?
- Yes. Clin2 currently lists 403 recruiting non-small cell lung cancer with egfr mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-small cell lung cancer with egfr mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-small cell lung cancer with egfr mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- EGFR Mutant Advanced Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.